Overview

JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.

Status:
NOT_YET_RECRUITING

Trial end date:
2029-12-31

Target enrollment:

Participant gender:

Summary

The primary purpose of the study was to compare progression-free survival of JYP0322 vs. platinum-based doublet chemotherapy in patients previously treated with ROS1-TKIs. Patients in the chemotherapy arm are given the option to switch to JYP0322 after BICR confirmed progressive disease (PD), while also have the choice to pursue with other drugs after discussing with their physicians.

Phase:

PHASE3

Details

Lead Sponsor:

Guangzhou JOYO Pharma Co., Ltd

Treatments:

Pemetrexed